This week, Andreas Munk Holm talks with Sergey Jakimov, Co-founder and Managing Partner at LongeVC, a leading longevity-focused venture fund backing breakthroughs in biotech, AI-driven drug discovery, and the science of healthy aging.

From pre-seed biotech spin-outs to multi-hundred-million-dollar exits with Big Pharma, LongeVC is building the category-defining fund at the frontier of life extension. In this episode, Sergey walks us through the team’s 3x+ MOIC track record, how LongeVC’s scientific advisory board unlocks proprietary deal flow, and why longevity and healthspan investing could be venture’s next trillion-dollar frontier.

🎧 Here’s what’s covered

01:15 – Who is Sergey Jakimov? From biotech entrepreneur to longevity investor
03:00 – What is LongeVC: thesis, structure, and Fund II snapshot
06:20 – The market for longevity & age-related disease: a $1.6 trillion opportunity
09:30 – Track record: Fund I’s 3x+ MOIC, 0 write-offs, 20 portfolio companies
12:40 – How LongeVC sources deals: scientific advisory board and AI-driven diligence
15:15 – Ecosystem advantage: from nonprofits to physician networks
18:00 – Case study 1 – Insilico Medicine, the $1.5 billion AI-drug-discovery unicorn
20:15 – Case study 2 – Turn Biotechnologies and $300 million + HanAll partnership
22:30 – Case study 3 – Rubedo Life Sciences and Beiersdorf’s dermatology deal
25:00 – How pharma’s pipeline erosion fuels biotech M&A
28:10 – Fund II: $120 million target, 20 % carry, 10-year term
31:20 – LP privileges: access, co-investments, and semi-annual IC observation
34:00 – Sergey’s vision: longevity as both moral and financial imperative

Sergey Jakimov, LongeVC: Impacting Lives Through Longevity & Health Investing

EUVC